Sfoglia per Autore
p27/Kip.1 ubiquitin ligase subunit skp2 relationships with cell proliferation and p27/Kip.1 expression in gliomas
2001-01-01 Schiffer, D.; Cavalla, P.; Fiano, V.; Vercellino, M.; Piva, R.; Pagano, M.
The recognition of different pathways to apoptosis in gliomas migth have different biological significances
2001-01-01 Schiffer, D.; Fiano, V.; Ghimenti, C.; Cavalla, P.
The uncertain definitions of oligodendrogliomas influence the evaluation of the efficacy of therapies
2001-01-01 Schiffer, D.; Cavalla, P.; Fiano, V.; Ghimenti, C.
Relationship between apoptosis and caspase 3 expression in malignant gliomas
2001-01-01 Schiffer D.; Fiano V.; Ghimenti C.; Cavalla P.
The role of caspase-3 in the pathways to apoptosis in gliomas
2001-01-01 Fiano, V.; Ghimenti, C.; Cavalla, P.; Schiffer, D.
Cyclins, CDKs and their inhibitor p27/Kip.1 in normal and neoplastic oligodendroglia
2002-01-01 Schiffer, D.; Fiano, V.; Ghimenti, C.; Cavalla, P.
Cyclins D1 and p27/Kip.1 in the differential diagnosis of diffuse astrocytomas and oligodendrogliomas
2002-01-01 Fiano, V.; Ghimenti, C.; Cavalla, P.; Schiffer, D.
p14ARF/Mdm2/p53 pathway deregulation in two glioblastoma series: with and without differentiated areas
2002-01-01 Ghimenti, C.; Fiano, V.; Chiadò-piat, L.; Cavalla, P.; Schiffer, D.
F-box protein Skp2 is not the only pathway for p27/Kip.1 degradation
2002-01-01 Cavalla, P.; Fiano, V.; Ghimenti, C.; Mutani, R.; Schiffer, D.
Cyclins and CDKs in classic and anaplastic oligodendroglioma
2003-01-01 Cavalla, P; Fiano, V; Schiffer, D.
Neurodegeneration and iron accumulation in deep grey matter nuclei in multiple sclerosis.
2011-01-01 Vercellino M; Trebini C; Romagnolo A; Chiavazza C; Masera S; Mattioda A; Capello E; Mancardi G; Giobbe D; Mutani R; Giordana MT; Cavalla P
How to treat MS patients after the 24th natalizumab administration: the TY-STOP trial
2014-01-01 Durelli, L.; De Mercanti, S.F.; Sormani, M.P.; Piazza, F.; Schiavetti, I.; Gned, D.; Brescia Morra, V.; Lanzillo, R.; Amato, L.; Quarantelli, M.; Ghezzi, A.; Bianchi, A.; Baroncini, D.; Salemi, G.; Realmuto, S.; Ferrò, M.T.; Vitetta, F.; Superti, G.; Cavalla, P.; D’Onghia, M.; Paolicelli, D.; Pinessi, L.; Trojano, M.; Clerico, M.
Treatment of multiple sclerosis patients after 24 Natalizumab doses: a prospective observational study: the TY-STOP
2014-01-01 Clerico, M; Schiavetti, I; De Mercanti, Sf; Piazza, F; Gned, D; Brescia Morra, V; Lanzillo, R; Ghezzi, A; Bianchi, A; Salemi, G; Realmuto, S; Sola, P; Vitetta, F; Cavalla, P; Superti, G; Ferraro, D; Paolicelli, D; Trojano, M; Sormani, Mp; Durelli, L
Natalizumab Therapy, How to Treat How to Stop: The TY-STOP Study
2014-01-01 Clerico, M.; De Mercanti, S.; Piazza, F.; Virgilio, E.; Gned, D.; Brescia Morra, V.; Lanzillo, R.; Amato, L.; Quarantelli, M.; Ghezzi, A.; Bianchi, A.; Baroncini, D.; Salemi, G.; Realmuto, S.; Ferrò, M.T.; Vitetta, F.; Superti, G.; Cavalla, P.; D'Onghia, M.; Paolicelli, D.; Schiavetti, I.; Sormani, M.P.; Pinessi, L.; Trojano, M.; Durelli, L.
The phagocyte functional impairment in treated multiple sclerosis patients.
2015-01-01 ALLIZOND V.; SCUTERA S.; ROSSI S.; MUSSO T.; CAVALLA P.; TREBINI C.; CROCILLÀ C.; CUFFINI A.M.; BANCHE G.
Role of multiple sclerosis treatment on neutrophil multifaceted functions against bacteria.
2016-01-01 Allizond, V.; Scutera, S.; Piersigilli, G.; Musso, T.; Cavalla, P.; Trebini, C.; Marra, E.S.; Cristina, C.; Cuffini, A.M.; Banche, G
NEW INSIGHTS INTO THE ROLE OF MULTIPLE SCLEROSIS TREATMENT ON POLYMORPHONUCLEAR LEUKOCYTE FUNCTIONS AGAINST PATHOGENS
2016-01-01 Allizond, V; Scutera, S; Piersigilli, G; Musso, T; Cavalla, P; Trebini, C; Marra, Es; Tullio, V; Mandras, N; Roana, J; Cuffini, Am; Banche, G
Inflammatory responses in Multiple Sclerosis normal-appearing white matter and in non-immune mediated neurological conditions with wallerian axonal degeneration: A comparative study
2017-01-01 Vercellino, M; Trebini, C; Capello, E; Mancardi, G. L; Giordana, M. T; Cavalla, P.
Specialist palliative care improves the quality of life in advanced neurodegenerative disorders: NE-PAL, a pilot randomised controlled study
2017-01-01 Veronese, Simone; Gallo, G; Valle, A; Cugno, C; Chiò, A; Calvo, A; Cavalla, P; Zibetti, M; Rivoiro, C; Oliver, D J
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| p27/Kip.1 ubiquitin ligase subunit skp2 relationships with cell proliferation and p27/Kip.1 expression in gliomas | 2001 | Schiffer, D.; Cavalla, P.; Fiano, V.; Vercellino, M.; Piva, R.; Pagano, M. | |
| The recognition of different pathways to apoptosis in gliomas migth have different biological significances | 2001 | Schiffer, D.; Fiano, V.; Ghimenti, C.; Cavalla, P. | |
| The uncertain definitions of oligodendrogliomas influence the evaluation of the efficacy of therapies | 2001 | Schiffer, D.; Cavalla, P.; Fiano, V.; Ghimenti, C. | |
| Relationship between apoptosis and caspase 3 expression in malignant gliomas | 2001 | Schiffer D.; Fiano V.; Ghimenti C.; Cavalla P. | |
| The role of caspase-3 in the pathways to apoptosis in gliomas | 2001 | Fiano, V.; Ghimenti, C.; Cavalla, P.; Schiffer, D. | |
| Cyclins, CDKs and their inhibitor p27/Kip.1 in normal and neoplastic oligodendroglia | 2002 | Schiffer, D.; Fiano, V.; Ghimenti, C.; Cavalla, P. | |
| Cyclins D1 and p27/Kip.1 in the differential diagnosis of diffuse astrocytomas and oligodendrogliomas | 2002 | Fiano, V.; Ghimenti, C.; Cavalla, P.; Schiffer, D. | |
| p14ARF/Mdm2/p53 pathway deregulation in two glioblastoma series: with and without differentiated areas | 2002 | Ghimenti, C.; Fiano, V.; Chiadò-piat, L.; Cavalla, P.; Schiffer, D. | |
| F-box protein Skp2 is not the only pathway for p27/Kip.1 degradation | 2002 | Cavalla, P.; Fiano, V.; Ghimenti, C.; Mutani, R.; Schiffer, D. | |
| Cyclins and CDKs in classic and anaplastic oligodendroglioma | 2003 | Cavalla, P; Fiano, V; Schiffer, D. | |
| Neurodegeneration and iron accumulation in deep grey matter nuclei in multiple sclerosis. | 2011 | Vercellino M; Trebini C; Romagnolo A; Chiavazza C; Masera S; Mattioda A; Capello E; Mancardi G; Giobbe D; Mutani R; Giordana MT; Cavalla P | |
| How to treat MS patients after the 24th natalizumab administration: the TY-STOP trial | 2014 | Durelli, L.; De Mercanti, S.F.; Sormani, M.P.; Piazza, F.; Schiavetti, I.; Gned, D.; Brescia Morra, V.; Lanzillo, R.; Amato, L.; Quarantelli, M.; Ghezzi, A.; Bianchi, A.; Baroncini, D.; Salemi, G.; Realmuto, S.; Ferrò, M.T.; Vitetta, F.; Superti, G.; Cavalla, P.; D’Onghia, M.; Paolicelli, D.; Pinessi, L.; Trojano, M.; Clerico, M. | |
| Treatment of multiple sclerosis patients after 24 Natalizumab doses: a prospective observational study: the TY-STOP | 2014 | Clerico, M; Schiavetti, I; De Mercanti, Sf; Piazza, F; Gned, D; Brescia Morra, V; Lanzillo, R; Ghezzi, A; Bianchi, A; Salemi, G; Realmuto, S; Sola, P; Vitetta, F; Cavalla, P; Superti, G; Ferraro, D; Paolicelli, D; Trojano, M; Sormani, Mp; Durelli, L | |
| Natalizumab Therapy, How to Treat How to Stop: The TY-STOP Study | 2014 | Clerico, M.; De Mercanti, S.; Piazza, F.; Virgilio, E.; Gned, D.; Brescia Morra, V.; Lanzillo, R.; Amato, L.; Quarantelli, M.; Ghezzi, A.; Bianchi, A.; Baroncini, D.; Salemi, G.; Realmuto, S.; Ferrò, M.T.; Vitetta, F.; Superti, G.; Cavalla, P.; D'Onghia, M.; Paolicelli, D.; Schiavetti, I.; Sormani, M.P.; Pinessi, L.; Trojano, M.; Durelli, L. | |
| The phagocyte functional impairment in treated multiple sclerosis patients. | 2015 | ALLIZOND V.; SCUTERA S.; ROSSI S.; MUSSO T.; CAVALLA P.; TREBINI C.; CROCILLÀ C.; CUFFINI A.M.; BANCHE G. | |
| Role of multiple sclerosis treatment on neutrophil multifaceted functions against bacteria. | 2016 | Allizond, V.; Scutera, S.; Piersigilli, G.; Musso, T.; Cavalla, P.; Trebini, C.; Marra, E.S.; Cristina, C.; Cuffini, A.M.; Banche, G | |
| NEW INSIGHTS INTO THE ROLE OF MULTIPLE SCLEROSIS TREATMENT ON POLYMORPHONUCLEAR LEUKOCYTE FUNCTIONS AGAINST PATHOGENS | 2016 | Allizond, V; Scutera, S; Piersigilli, G; Musso, T; Cavalla, P; Trebini, C; Marra, Es; Tullio, V; Mandras, N; Roana, J; Cuffini, Am; Banche, G | |
| Inflammatory responses in Multiple Sclerosis normal-appearing white matter and in non-immune mediated neurological conditions with wallerian axonal degeneration: A comparative study | 2017 | Vercellino, M; Trebini, C; Capello, E; Mancardi, G. L; Giordana, M. T; Cavalla, P. | |
| Specialist palliative care improves the quality of life in advanced neurodegenerative disorders: NE-PAL, a pilot randomised controlled study | 2017 | Veronese, Simone; Gallo, G; Valle, A; Cugno, C; Chiò, A; Calvo, A; Cavalla, P; Zibetti, M; Rivoiro, C; Oliver, D J |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile